Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
PublisherInternational Institute of Anticancer Research
MetadataShow full item record
AbstractBACKGROUND/AIM: Poly (ADP-ribose) polymerase inhibitors (PARPis) are one of the targeted therapies proven to treat breast cancer gene (BRCA)-mutant ovarian cancer. Because most ovarian cancers are BRCA wild-type, it is necessary to extend the usage of PARPis. In the present study, we combined the PARPi, talazoparib, and the IL-6 inhibitor, bazedoxifene, for the treatment of human ovarian cancer cells. MATERIALS AND METHODS: The human ovarian cancer cell lines, SKOV3, UWB1.289 (BRCA1-null) and OV75, were treated with talazoparib and bazedoxifene, as monotherapy or combination treatment. The effects of treatment on cell viability, migration, growth and colony formation were examined. Western blot was used to investigate pathways that may be involved in the antitumor effects of the two agents. RESULTS: The combination of talazoparib and bazedoxifene showed synergistic inhibition of cell viability, cell migration, cell growth, and cell colony formation on all the studied cell lines. The expression of p-AKT, c-myc, p-ERK, ERα was inhibited, and γ-H2AX expression was induced. CONCLUSION: Combined inhibition of PARP and IL-6 may be an efficacious treatment for ovarian cancer, independently of BRCA mutation status.
Rights/TermsCopyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15695
- An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
- Authors: Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP
- Issue date: 2018 Jul 1
- PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer.
- Authors: Dickson KA, Xie T, Evenhuis C, Ma Y, Marsh DJ
- Issue date: 2021 Aug 7
- Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
- Authors: Cho HY, Kim YB, Park WH, No JH
- Issue date: 2021 Jul
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
- Authors: Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D
- Issue date: 2018 Jun
- Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
- Authors: Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R
- Issue date: 2016 Aug